These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Retinoid X receptor agonists inhibit hypertension-induced myocardial hypertrophy by modulating LKB1/AMPK/p70S6K signaling pathway. Zhu J; Ning RB; Lin XY; Chai DJ; Xu CS; Xie H; Zeng JZ; Lin JX Am J Hypertens; 2014 Aug; 27(8):1112-24. PubMed ID: 24603314 [TBL] [Abstract][Full Text] [Related]
26. Role of bexarotene in the treatment of cutaneous T-cell lymphoma: the clinical and immunological sides. Pileri A; Delfino C; Grandi V; Pimpinelli N Immunotherapy; 2013 Apr; 5(4):427-33. PubMed ID: 23557425 [TBL] [Abstract][Full Text] [Related]
27. A selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced prostate cancer. Yen WC; Lamph WW Prostate; 2006 Feb; 66(3):305-16. PubMed ID: 16245282 [TBL] [Abstract][Full Text] [Related]
28. Central hypothyroidism associated with retinoid X receptor-selective ligands. Sherman SI; Gopal J; Haugen BR; Chiu AC; Whaley K; Nowlakha P; Duvic M N Engl J Med; 1999 Apr; 340(14):1075-9. PubMed ID: 10194237 [TBL] [Abstract][Full Text] [Related]
29. Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. Esteva FJ; Glaspy J; Baidas S; Laufman L; Hutchins L; Dickler M; Tripathy D; Cohen R; DeMichele A; Yocum RC; Osborne CK; Hayes DF; Hortobagyi GN; Winer E; Demetri GD J Clin Oncol; 2003 Mar; 21(6):999-1006. PubMed ID: 12637463 [TBL] [Abstract][Full Text] [Related]
30. Possible Molecular Interactions of Bexarotene - A Retinoid Drug and Alzheimer's Aβ Peptide: A Docking Study. Mirza Z; Beg MA Curr Alzheimer Res; 2017; 14(3):327-334. PubMed ID: 27842487 [TBL] [Abstract][Full Text] [Related]
32. The novel function of bexarotene for neurological diseases. Liu Y; Wang P; Jin G; Shi P; Zhao Y; Guo J; Yin Y; Shao Q; Li P; Yang P Ageing Res Rev; 2023 Sep; 90():102021. PubMed ID: 37495118 [TBL] [Abstract][Full Text] [Related]
33. A selective retinoid X receptor agonist bexarotene (Targretin) prevents and overcomes acquired paclitaxel (Taxol) resistance in human non-small cell lung cancer. Yen WC; Corpuz MR; Prudente RY; Cooke TA; Bissonnette RP; Negro-Vilar A; Lamph WW Clin Cancer Res; 2004 Dec; 10(24):8656-64. PubMed ID: 15623650 [TBL] [Abstract][Full Text] [Related]
34. Novel silicon-containing analogues of the retinoid agonist bexarotene: syntheses and biological effects on human pluripotent stem cells. Bauer JB; Lippert WP; Dörrich S; Tebbe D; Burschka C; Christie VB; Tams DM; Henderson AP; Murray BA; Marder TB; Przyborski SA; Tacke R ChemMedChem; 2011 Aug; 6(8):1509-17. PubMed ID: 21726055 [TBL] [Abstract][Full Text] [Related]
35. A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC). Rodon J; Jacobs CD; Chu Q; Rowinsky EK; Lopez-Anaya A; Takimoto CH; Wakelee HA Cancer Chemother Pharmacol; 2012 Mar; 69(3):825-34. PubMed ID: 22057853 [TBL] [Abstract][Full Text] [Related]
36. Bexarotene in cutaneous T-cell lymphoma: third retrospective study of long-term cohort and review of the literature. Quéreux G; Saint-Jean M; Peuvrel L; Brocard A; Knol AC; Dréno B Expert Opin Pharmacother; 2013 Sep; 14(13):1711-21. PubMed ID: 23837676 [TBL] [Abstract][Full Text] [Related]
37. Bexarotene prodrugs: targeting through cleavage by NQO1 (DT-diaphorase). Schäfer A; Burstein ES; Olsson R Bioorg Med Chem Lett; 2014 Apr; 24(8):1944-7. PubMed ID: 24666648 [TBL] [Abstract][Full Text] [Related]
38. Bexarotene nanocrystal-Oral and parenteral formulation development, characterization and pharmacokinetic evaluation. Chen L; Wang Y; Zhang J; Hao L; Guo H; Lou H; Zhang D Eur J Pharm Biopharm; 2014 May; 87(1):160-9. PubMed ID: 24333772 [TBL] [Abstract][Full Text] [Related]